Governance Insmed Incorporated

INSM

US4576693075

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:39:48 05/03/2026 pm IST			5-day change	1st Jan Change
143.94 ^USD	-3.96%		-3.81%	-17.10%

02/03	Insmed Incorporated Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 09:50 AM
24/02	Insmed Insider Sold Shares Worth $1,615,257, According to a Recent SEC Filing	MT

Executive Committee: Insmed Incorporated

Manager

Positions heldSince

Will Lewis

57 year

Chief Executive Officer	10/09/2012
President	10/09/2012

Michael Smith

49 year

General Counsel	01/04/2014
Corporate Secretary	-

Sara Bonstein

45 year

Director of Finance/CFO

31/01/2020

Martina Flammer

62 year

Chief Tech/Sci/R&D Officer

19/12/2019

Walter R. Perkins

Chief Tech/Sci/R&D Officer

01/12/2010

Roger Adsett

57 year

Chief Operating Officer

14/11/2019

S. Schaeffer

57 year

Human Resources Officer

01/10/2012

Bryan Dunn

Investor Relations Contact

01/01/2025

Composition of the Board of Directors: Insmed Incorporated

Director

CommitteesSince

Will Lewis

57 year

Audit Committee	08/01/2024
Compensation Committee	08/01/2024
Governance Committee Chair	08/01/2024
Nominating Committee Chair	08/01/2024

Elizabeth Anderson

68 year

Compensation Committee Chair
Governance Committee Chair
Nominating Committee Chair
Governance Committee	10/07/2019
Audit Committee	01/09/2022
Compensation Committee	01/09/2022

Carol Schafer

62 year

Audit Committee	01/04/2020
Governance Committee	02/01/2024
Nominating Committee	02/01/2024
Audit Committee Chair	02/01/2024

David McGirr

71 year

Audit Committee Chair	01/11/2015
Governance Committee	01/11/2015
Nominating Committee	01/11/2015

Melvin Sharoky

75 year

Governance Committee	19/03/2014
Nominating Committee	19/03/2014

David Brennan

72 year

Compensation Committee Chair

30/05/2014

Yao Lee

56 year

Compensation Committee

17/05/2018

Clarissa Desjardins

59 year

Director/Board Member	01/11/2019
Independent Dir/Board Member	01/11/2019

Latest Appointments: Insmed Incorporated

18/25/18	J. Drayton Wise Notifies Insmed Incorporated to Resign from His Position as the Company?s Chief Commercial Officer	CI
23/22/23	Insmed Incorporated Names Drayton Wise as Chief Commercial Officer	CI
22/21/22	Insmed Incorporated Announces Executive Changes	CI
02/20/02	Insmed Incorporated Announces Board Changes	CI
30/20/30	Insmed Incorporated Appoints Sara Bonstein as Chief Financial Officer and a Member of Insmed's Executive Committee, Effective January 31, 2020	CI
14/19/14	Insmed Incorporated Announces Board Changes	CI
30/19/30	Insmed Incorporated Appoints Dr. Martina Flammer as Chief Medical Officer, Effective on or About December 19, 2019	CI

More news

Former Officers and Directors: Insmed Incorporated

Insider

Positions held

SinceUntil

Al Altomari

Director/Board Member	02/08/2012	15/05/2025
Independent Dir/Board Member	02/08/2012	15/05/2025

Drayton Wise

Corporate Officer/Principal	01/10/2016	16/04/2025
Sales & Marketing	01/10/2014	01/10/2016

John Goll

Comptroller/Controller/Auditor

02/04/2014

01/04/2023

Steinar Johan Engelsen

Director/Board Member	29/11/1999	11/05/2022
Independent Dir/Board Member	29/11/1999	11/05/2022

Zhanna Jumadilova

Corporate Officer/Principal

01/04/2019

01/10/2021

John D. Soriano

Compliance Officer

01/01/2018

01/10/2021

Christine Pellizzari

General Counsel	01/07/2013	07/07/2021
Corporate Secretary	01/07/2013	07/07/2021

Blaine Davis

Investor Relations Contact	01/07/2017	01/01/2020
Public Communications Contact	01/07/2017	01/01/2020

Paolo Tombesi

Director of Finance/CFO

01/06/2017

02/06/2019

Donald Hayden

Director/Board Member	08/11/2018	16/05/2019
Chairman	03/12/2010	08/11/2018
Independent Dir/Board Member	01/12/2010	08/11/2018

Paul Streck

Chief Tech/Sci/R&D Officer

05/06/2017

18/01/2019

Jason Hoitt

Sales & Marketing

01/05/2017

Myrtle Potter

Director/Board Member	15/12/2014	08/11/2018
Independent Dir/Board Member	15/12/2014	08/11/2018

Andrew Drechsler

Director of Finance/CFO

08/11/2012

01/03/2017

Randall Whitcomb

Director/Board Member	01/11/2001	01/05/2015
Independent Dir/Board Member	17/05/2012	01/05/2015

Matthew Pauls

Corporate Officer/Principal

01/04/2013

01/08/2014

Renu Gupta

Chief Tech/Sci/R&D Officer

09/12/2010

02/04/2014

Gina Eagle

Chief Tech/Sci/R&D Officer

01/04/2014

Peggy J. Berry

General Counsel

06/03/2014

Laura Edgerly-Pflug

Corporate Officer/Principal

20/01/2011

01/12/2013

Richard Kollender

Director/Board Member	12/01/2011	31/10/2013
Independent Dir/Board Member	12/01/2011	31/10/2013

Wesley Kaupinen

Corporate Officer/Principal

01/08/2013

Andrea Holtzman Drucker

General Counsel	19/07/2011	03/06/2013
Corporate Secretary	19/07/2011	03/06/2013

Peter M. Clarke

Chief Tech/Sci/R&D Officer	19/03/2014	-
Corporate Officer/Principal	07/05/2013	19/03/2014

Kevin P. Tully

Director of Finance/CFO	01/02/2006	08/11/2012
Corporate Officer/Principal	08/11/2012	01/12/2012
Comptroller/Controller/Auditor	01/08/2005	01/08/2005
Director of Finance/CFO	01/08/2005	01/08/2005
Treasurer	01/08/2005	01/08/2005

Nicholas LaBella

Chief Tech/Sci/R&D Officer

20/01/2011

05/10/2012

Timothy G. Whitten

Director/Board Member	03/12/2010	03/12/2010
President	03/12/2010	10/09/2012

Graham K. Crooke

Director/Board Member

29/11/1999

01/12/2010

Kenneth G. Condon

Director/Board Member

29/11/1999

01/12/2010

Denny Lanfear

Director/Board Member

06/12/2007

01/12/2010

Stephen Glover

Corporate Officer/Principal

01/01/2007

01/12/2010

Nicholas Lee Gurreri

Chief Operating Officer	09/07/2012	-
Corporate Officer/Principal	20/12/2010	09/07/2012

Dee Grosso

Human Resources Officer	11/02/2011	-
Corporate Officer/Principal	20/01/2011	11/02/2011

Geoffrey Allan

Chairman	29/11/1999	15/06/2009
President	29/11/1999	15/06/2009

Ronald D. Gunn

Chief Operating Officer

29/11/1999

11/01/2008

Philip Young

Corporate Officer/Principal

01/04/2004

07/03/2007

Kenneth Attie

Chief Tech/Sci/R&D Officer

01/01/2004

01/01/2007

Thomas Keuer

Chief Operating Officer

01/01/2004

01/11/2006

Hi Ewald

Chairman	01/01/1995	01/01/2002
Private Equity Investor	01/01/1995	01/01/2002

Glen L. Kelley

General Counsel

18/06/2009

Andreas Sommer

Chief Tech/Sci/R&D Officer

01/01/2000

Kevin Schutz

General Counsel

Kevin McDermott

Corporate Officer/Principal

Susan Mesco

Investor Relations Contact

Jill Dolgin

Corporate Officer/Principal

Katarina Easley

Human Resources Officer

14/12/2010

Daniel Brody

Director/Board Member

01/08/2013

Tage Ramakrishna

Chief Tech/Sci/R&D Officer

A. Stewart Campbell

Chief Tech/Sci/R&D Officer

Doug Farrar

Corporate Officer/Principal

Eleanor Barisser

Investor Relations Contact

Elaine Heron

Director/Board Member

Edgar Engleman

Director/Board Member

John Procter

Public Communications Contact

W. McIlwaine Thompson

Corporate Secretary

Kimberly Sheehan

Corporate Officer/Principal

Age distribution of managers

Parity Men Women

Male	12
Female	5

Of which Executive Committee

Male	6
Female	2

Of which Directors

Male	6
Female	2

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

Employees

1,664

Sector

Biotechnology & Medical Research

More about the company